$ADIL
ADIAL PHARMACEUTICALS, INC. Stock $adil

$adil Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000121390023086913 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.519M	$1.150M	$1.944M
YoY Change	-27.75%	-40.85%	-18.03%
% of Gross Profit
Research & Development	$264.4K	$207.1K	$1.244M
YoY Change	-76.74%	-83.34%	-26.49%
% of Gross Profit
Depreciation & Amortization	$560.00	$0.00	$2.070K
YoY Change	-73.08%	-100.0%	1378.57%
% of Gross Profit
Operating Expenses	$1.784M	$1.358M	$3.188M
YoY Change	-44.94%	-57.4%	-21.55%
Operating Profit		-$1.358M	-$3.188M
YoY Change		-57.4%	-21.55%
Interest Expense	-$182.7K	$10.00K	$3.340K
YoY Change	-481.97%	199.4%	16.78%
% of Operating Profit
Other Income/Expense, Net	$62.06K	$10.24K	$78.34K
YoY Change	-80.9%	-86.93%	-130.47%
Pretax Income	-$1.904M	-$1.348M	-$3.109M
YoY Change	-33.58%	-56.66%	-27.99%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$1.920M	-$1.385M	-$3.109M
YoY Change	-33.01%	-55.46%	-27.99%
Net Earnings / Revenue
Basic Earnings Per Share		-$1.18	-$0.12
Diluted Earnings Per Share	-$1.34	-$1.18	-$0.12
COMMON SHARES
Basic Shares Outstanding	1.218M shares	1.218M shares	25.85M shares
Diluted Shares Outstanding		1.179M shares	25.72M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.827M	$320.0K	$5.753M
YoY Change	-29.35%	-94.44%	-19.88%
Cash & Equivalents	$2.827M	$315.9K	$5.753M
Short-Term Investments
Other Short-Term Assets	$371.6K	$470.0K	$1.021M
YoY Change	-52.25%	-53.95%	26.73%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$3.199M	$1.135M	$6.773M
YoY Change	-33.08%	-83.24%	-15.18%
LONG-TERM ASSETS
Property, Plant & Equipment			$52.36K
YoY Change			-83.67%
Goodwill			$249.0K
YoY Change
Intangibles	$3.913K
YoY Change
Long-Term Investments	$1.534M	$1.728M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.538M	$1.732M	$968.4K
YoY Change	61.4%	78.84%	-60.64%
TOTAL ASSETS
Total Short-Term Assets	$3.199M	$1.135M	$6.773M
Total Long-Term Assets	$1.538M	$1.732M	$968.4K
Total Assets	$4.737M	$2.867M	$7.742M
YoY Change	-17.38%	-62.96%	-25.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$127.4K	$81.93K	$278.2K
YoY Change	-67.65%	-70.55%	50.22%
Accrued Expenses	$525.7K	$408.6K	$955.4K
YoY Change	-54.48%	-57.23%	-46.1%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$653.1K	$528.2K	$1.327M
YoY Change	-63.53%	-60.2%	-32.22%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities			$982.3K
YoY Change			-23.75%
Total Long-Term Liabilities	$0.00	$0.00	$982.3K
YoY Change	-100.0%	-100.0%	-23.75%
TOTAL LIABILITIES
Total Short-Term Liabilities	$653.1K	$528.2K	$1.327M
Total Long-Term Liabilities	$0.00	$0.00	$982.3K
Total Liabilities	$653.1K	$528.2K	$2.333M
YoY Change	-73.41%	-77.36%	-28.14%
SHAREHOLDERS EQUITY
Retained Earnings	-$68.80M	-$66.88M	-$60.81M
YoY Change	8.05%	9.98%
Common Stock	$1.663K	$1.218K	$26.85K
YoY Change	-93.77%	-95.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.084M	$2.339M	$5.409M
YoY Change
Total Liabilities & Shareholders Equity	$4.737M	$2.867M	$7.742M
YoY Change	-17.38%	-62.96%	-25.89%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$1.920M	-$1.385M	-$3.109M
YoY Change	-33.01%	-55.46%	-27.99%
Depreciation, Depletion And Amortization	$560.00	$0.00	$2.070K
YoY Change	-73.08%	-100.0%	1378.57%
Cash From Operating Activities	-$1.227M	-$1.390M	-$3.404M
YoY Change	-29.93%	-59.17%	-3.56%
INVESTING ACTIVITIES
Capital Expenditures			$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$350.0K	$350.0K	$0.00
YoY Change
Cash From Investing Activities	$350.0K	$350.0K	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.382M	140.0K	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-1.227M	-1.390M	-3.404M
Cash From Investing Activities	350.0K	350.0K	0.000
Cash From Financing Activities	3.382M	140.0K	0.000
Net Change In Cash	2.505M	-900.0K	-3.404M
YoY Change	-243.09%	-73.56%	-272.76%
FREE CASH FLOW
Cash From Operating Activities	-$1.227M	-$1.390M	-$3.404M
Capital Expenditures			$0.00
Free Cash Flow			-$3.404M
YoY Change			-3.56%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments		usd
CY2023Q3	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent		usd
CY2023Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38323
	dei	Entity Registrant Name EntityRegistrantName	ADIAL PHARMACEUTICALS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3074668
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1180 Seminole Trail
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 495
	dei	Entity Address City Or Town EntityAddressCityOrTown	Charlottesville
	dei	Entity Address State Or Province EntityAddressStateOrProvince	VA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	22901
	dei	City Area Code CityAreaCode	(434)
	dei	Local Phone Number LocalPhoneNumber	422-9800
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1217981	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	315880	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4001794	usd
CY2023Q3	us-gaap	Accounts Receivable From Securitization AccountsReceivableFromSecuritization	350000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	469606	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	349441	usd
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	428700	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	1135486	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	4779935	usd
CY2023Q3	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	4054	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	4477	usd
CY2023Q3	us-gaap	Equity Method Investments EquityMethodInvestments	1727897	usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	948392	usd
CY2023Q3	us-gaap	Assets Assets	2867437	usd
CY2022Q4	us-gaap	Assets Assets	5732804	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	81925	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	276410	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	408614	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	963327	usd
CY2023Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	30000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	175000	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	7640	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	10387	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	365742	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	528179	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1790866	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1690	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	663754	usd
CY2023Q3	us-gaap	Liabilities Liabilities	528179	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2456310	usd
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1217981	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1217981	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1067491	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1067491	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	1218	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1067	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	69215579	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	66949958	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-66877539	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-63674531	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	2339258	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3276494	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2867437	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5732804	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	207128	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	696073	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1002640	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1418467	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1150808	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1858550	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4101466	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6843513	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	1357936	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	2554623	usd
	us-gaap	Operating Expenses OperatingExpenses	5104106	usd
	us-gaap	Operating Expenses OperatingExpenses	8261980	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1357936	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2554623	usd
CY2023Q3	adil	Clinical Research Organization Services And Expenses ClinicalResearchOrganizationServicesAndExpenses		usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5104106	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8261980	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	10236	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	3472	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	58554	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	15517	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	51901	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	10236	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3472	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6653	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	15517	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1347700	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2551151	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5097453	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8246463	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-1347700	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-2551151	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-5097453	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-8246463	usd
CY2023Q3	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	37276	usd
CY2022Q3	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	558199	usd
	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	-1894445	usd
	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	1618258	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1384976	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3109350	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3203008	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9864721	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.14
CY2022Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-2.48
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-4.54
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-8.31
CY2023Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.03
CY2022Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.54
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	1.69
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-1.63
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.18
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.86
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-9.94
CY2023Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	1178537	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	1028982	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	1121328	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	992156	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3276494	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	397442	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	62135	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	609613	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2905836	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1439848	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	310263	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	427317	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	51901	usd
CY2023Q2	adil	Warrants Exercised WarrantsExercised	58	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	1087804	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	3317191	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	293665	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	49526	usd
CY2023Q3	adil	Equitybased Compensation Forfeiture Of Unvested Stock Issuances On Employee Termination EquitybasedCompensationForfeitureOfUnvestedStockIssuancesOnEmployeeTermination	-74817	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	140330	usd
CY2023Q3	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	1661	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1384976	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	2339258	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3507811	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	567189	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	416423	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	9123741	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2907839	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	10707325	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	625816	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	473906	usd
CY2022Q2	adil	Warrants Exercised WarrantsExercised	1865	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-3847532	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	7961380	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	477868	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	79147	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3109350	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	5409045	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-5097453	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-8246463	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1465531	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2640349	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	51901	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	423	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	423	usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	1690	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	120165	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	114738	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-9931	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-554713	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1523685	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-145000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	30000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-197232	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	14749	usd
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4598398	usd
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-7189434	usd
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-985856	usd
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-2245680	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5584254	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9435114	usd
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	1150000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1150000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	749943	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9123741	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	58	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1865	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1661	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	748340	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9125606	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-3685914	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-309508	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4001794	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6062173	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	315880	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5752665	usd
	adil	Equity Consideration Received For Sale Of Purnovate EquityConsiderationReceivedForSaleOfPurnovate	1727897	usd
	adil	Reimbursement Receivable In Connection With Sale Of Purnovate ReimbursementReceivableInConnectionWithSaleOfPurnovate	737276	usd
CY2023Q2	us-gaap	Fee Income FeeIncome	450000	usd
	us-gaap	Reimbursement From Limited Partnership Investment ReimbursementFromLimitedPartnershipInvestment	350000	usd
CY2023Q3	us-gaap	Reimbursement From Limited Partnership Investment ReimbursementFromLimitedPartnershipInvestment	350000	usd
CY2023Q4	us-gaap	Additions To Contract Holders Funds AdditionsToContractHoldersFunds	350000	usd
CY2023Q4	adil	Net Proceeds NetProceeds	3500000	usd
CY2022Q3	adil	Annual Fee AnnualFee	430000	usd
CY2023Q3	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	108750	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Significant items subject to such estimates and assumptions include the valuation of the equity method investment and the valuation of stock-based compensation.</p>
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	329022	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	483834	shares
	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	204059	shares
	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	172679	shares
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	26667	shares
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	47777	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	559748	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	704290	shares
CY2023Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	141000	usd
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	3800000	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	326250	usd
CY2022Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	103750	usd
CY2023Q2	us-gaap	Payments For Fees PaymentsForFees	450000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Other Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments	350000	usd
CY2023Q3	us-gaap	Proceeds From Maturities Prepayments And Calls Of Other Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments	350000	usd
CY2023Q4	us-gaap	Ceded Premiums Payable CededPremiumsPayable	350000	usd
CY2023Q2	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	1727897	usd
CY2023Q3	adil	Total Consideration Paid TotalConsiderationPaid	3227897	usd
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	291250	usd
CY2023Q3	us-gaap	Other Commitment OtherCommitment	209250	usd
CY2023Q2	us-gaap	Equity Ownership Percentage Excluding Consolidated Entity And Equity Method Investee EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee	0.15	pure
CY2023Q2	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	4000000	usd
CY2023Q3	us-gaap	Equity Issued In Business Combination Fair Value Disclosure EquityIssuedInBusinessCombinationFairValueDisclosure	1727897	usd
	us-gaap	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Equity Interests BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests	1727897	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	222656	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	219798	usd
	us-gaap	Equity Method Investment Sold Carrying Amount EquityMethodInvestmentSoldCarryingAmount	1727897	usd
CY2023Q3	us-gaap	Equity Method Investments EquityMethodInvestments	1727897	usd
	us-gaap	Charity Care Reimbursements Received CharityCareReimbursementsReceived	350000	usd
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	921356	usd
	adil	Weighted Average Remaining Service Period WeightedAverageRemainingServicePeriod	P2Y
CY2023Q1	us-gaap	Deferred Compensation Arrangement With Individual Distribution Paid DeferredCompensationArrangementWithIndividualDistributionPaid	22000	usd
	us-gaap	Stock Granted During Period Value Sharebased Compensation Forfeited StockGrantedDuringPeriodValueSharebasedCompensationForfeited	4000	usd
CY2022Q4	adil	Clinical Research Organization Services And Expenses ClinicalResearchOrganizationServicesAndExpenses	123386	usd
CY2023Q3	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	354107	usd
CY2022Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	761509	usd
CY2023Q3	adil	Legal And Consulting Services LegalAndConsultingServices	48691	usd
CY2022Q4	adil	Legal And Consulting Services LegalAndConsultingServices	72616	usd
CY2023Q3	adil	Manufacturing Expenses ManufacturingExpenses	-5816	usd
CY2022Q4	adil	Manufacturing Expenses ManufacturingExpenses	-5816	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	408614	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	963327	usd
CY2023Q2	us-gaap	Line Of Credit Facility Commitment Fee Amount LineOfCreditFacilityCommitmentFeeAmount	3000000	usd
CY2023Q2	us-gaap	Additional Collateral Aggregate Fair Value AdditionalCollateralAggregateFairValue	500000	usd
CY2023Q2	adil	Daily Trading Value DailyTradingValue	2000000	usd
CY2023Q2	adil	Weighted Average Price Percentage WeightedAveragePricePercentage	0.95	pure
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	51901	usd
CY2023Q1	adil	Aggregate Purchase Price AggregatePurchasePrice	750000	usd
CY2023Q1	adil	Expenses Fees ExpensesFees	609613	usd
	adil	Unregistered Share Of Common Stock UnregisteredShareOfCommonStock	7317	shares
	adil	Percentage Of Aggregate Shares PercentageOfAggregateShares	0.10	pure
	adil	Common Stock Issuances CommonStockIssuances	The Placement Agent Warrants have an exercise price equal to $10.25 and are exercisable two months after the closing date and expire five years after the date of issuance.
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	58540	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023Q3	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	39800	shares
	us-gaap	Dividends Common Stock Stock DividendsCommonStockStock	243157	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	268374	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	557015	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1465531	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2640349	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	486726	shares
	adil	Weighted Average Remaining Term Outstanding Begining Balance WeightedAverageRemainingTermOutstandingBeginingBalance	P3Y14D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	100.75
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue	0.25
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	7317	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5
	adil	Weighted Average Exercise Price Issued WeightedAverageExercisePriceIssued	10.25
	adil	Average Intrinsic Value Issuedin Shares AverageIntrinsicValueIssuedinShares	0
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	433	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.13
	adil	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercised SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised	0.23
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	493610	shares
	adil	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Terms SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y3M21D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	99.5
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue	0
	adil	License Fees And Milestone Payments Description LicenseFeesAndMilestonePaymentsDescription	More specifically, the Company paid UVA LVG a license issue fee and is obligated to pay UVA LVG (i) annual minimum royalties of $40,000 commencing in 2017; (ii) a $20,000 milestone payments upon dosing the first patient under a Phase 3 human clinical trial of a licensed product, $155,000 upon the earlier of the completion of a Phase 3 trial of a licensed product, partnering of a licensed product, or sale of the Company, $275,000 upon acceptance of an NDA by the FDA, and $1,000,000 upon approval for sale of AD04 in the U.S., Europe or Japan; as well as (iii) royalties equal to a 2% and 1% of net sales of licensed products in countries in which a valid patent exists or does not exist, respectively, with royalties paid quarterly. In the event of a sublicense to a third party, the Company is obligated to pay royalties to UVA LVG equal to a percentage of what the Company would have been required to pay to UVA LVG had it sold the products under sublicense itself. In addition, the Company is required to pay to UVA LVG 15% of any sublicensing income.
	us-gaap	Royalty Expense RoyaltyExpense	30000	usd
	us-gaap	Royalty Expense RoyaltyExpense	30000	usd
	adil	Master Services Agreement Description MasterServicesAgreementDescription	The MSA has a term of five years, automatically renewed for two-year periods, unless either party gives written notice of a decision not to renew the agreement six months prior to automatic renewal.
	adil	Unaccrued Expense UnaccruedExpense	20299	usd
	adil	Annual Fee AnnualFee	375000	usd
	us-gaap	Restructuring Costs RestructuringCosts	143100	usd
CY2023Q3	adil	Future Cash FutureCash	302000	usd
CY2022Q4	us-gaap	Accounts Receivable From Securitization AccountsReceivableFromSecuritization		usd
CY2023Q3	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent		usd
CY2023Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet		usd
CY2022Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense		usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-0.54
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.18
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.86
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1028982	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1121328	shares
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives		usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther		usd
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
	adil	Equity Consideration Received For Sale Of Purnovate EquityConsiderationReceivedForSaleOfPurnovate		usd
	adil	Reimbursement Receivable In Connection With Sale Of Purnovate ReimbursementReceivableInConnectionWithSaleOfPurnovate		usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments		usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001513525

Files In Submission

Name	View Source	Status
0001213900-23-086913-index-headers.html	Edgar Link	pending
0001213900-23-086913-index.html	Edgar Link	pending
0001213900-23-086913.txt	Edgar Link	pending
0001213900-23-086913-xbrl.zip	Edgar Link	pending
adil-20230930.xsd	Edgar Link	pending
adil-20230930_pre.xml	Edgar Link	unprocessable
adil-20230930_cal.xml	Edgar Link	unprocessable
adil-20230930_lab.xml	Edgar Link	unprocessable
adil-20230930_def.xml	Edgar Link	unprocessable
f10q0923ex31-1_adialpharma.htm	Edgar Link	pending
f10q0923ex31-2_adialpharma.htm	Edgar Link	pending
f10q0923ex32-1_adialpharma.htm	Edgar Link	pending
f10q0923ex32-2_adialpharma.htm	Edgar Link	pending
f10q0923_adialpharma.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
f10q0923_adialpharma_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ADIL
ADIAL PHARMACEUTICALS, INC. Stock $adil

2023 Q4 Form 10-Q Financial Statement

#000121390023086913 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADIL ADIAL PHARMACEUTICALS, INC. Stock $adil

2023 Q4 Form 10-Q Financial Statement

#000121390023086913 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADIL
ADIAL PHARMACEUTICALS, INC. Stock $adil